Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

eiF2B Activators to Treat Noise-Induced Hearing Loss

Award Number: R44DC020069
ORGANIZATION: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

eiF2B Activators to Treat Noise-Induced Hearing Loss - ABSTRACT Noise induced hearing loss (NIHL) is one of the most common types of acquired hearing loss in the US. Often stemming from occupations with elevated noise environments like construction sites, manufacturing plants, law enforcement agencies, armed forces, and aviation, NIHL emerges as a significant public health concern. Furthermore, recreational activities involving amplified music, firearms, and motorized vehicles also contribute to this auditory impairment. Indeed, an estimated 10-15% of Americans aged 20 to 69 exhibit varying degrees of hearing deterioration linked to high noise. Currently NIHL has no approved therapeutical treatments. A recent legal suit between 3M and the military was just settled today for $5.5 billion over military earplugs underscores this important linkage. Jacaranda Bioscience offers a distinctive solution that stands out not only due to the absence of existing treatments but also because our drug treatment runs through a cellular pathway (the Unfolded Protein Response or UPR) that has remained unexplored in this context. Our passionate commitment at Jacaranda Bioscience Inc. (JBI) is to lead the development of an innovative and effective therapy, thereby addressing NIHL in an unprecedented manner. Within this Phase II proposal, JBI will advance a highly effective small molecule therapeutic into preclinical development (JBI-015) as well as two backup compounds (JBI-016 and 028) with great therapeutic potential. The objective of Phase II is therefore to optimize these compounds, in preparation for an investigational new drug application. Our approach involves a rigorous process of medicinal chemistry, encompassing in-depth studies of Absorption, Distribution, Metabolism, and Excretion (ADME), Pharmacokinetics (PK), and formulation development. Additionally, we will conduct rigorous assessment of in vivo efficacy including their effects on cell viability, cell death, and cell toxicity. Importantly we will establish an oral formulation that will make future JBI compounds readily usable in the clinical marketplace. Upon the end of our grant period, our objective is to collect a robust dataset substantiating the rationale for initiating an Investigational New Drug (IND) application. This will pave the way ultimately for the progression into a human Phase 1 clinical trial, a significant stride towards realizing the potential of our therapeutic approach.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	JACARANDA BIOSCIENCES, INC	2908 BAKER ST	SAN FRANCISCO	CA	94123	SAN FRANCISCO	USA	Research Related to Deafness and Communication Disorders	000	2	12/3/2025	COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,554,254 )
2025	2025	JACARANDA BIOSCIENCES, INC	2908 BAKER ST	SAN FRANCISCO	CA	94123	SAN FRANCISCO	USA	Research Related to Deafness and Communication Disorders	000	2	5/1/2025	COMPETING CONTINUATION	$1,554,254
														Subtotal = $1,554,254

Grand Total All Awards = $1,554,254

Top

All Categories

About

Search

Reports

Data Submission

Award Information

eiF2B Activators to Treat Noise-Induced Hearing Loss

Award Number: R44DC020069

ORGANIZATION: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer